TRAFIKK: systematic prediction and mechanistic interpretation of anticancer drug synergies

Marco Fariñas(Norwegian University of Science and Technology), Viviam Bermudez(Norwegian University of Science and Technology), Eirini Tsirvouli(Norwegian University of Science and Technology), John Zobolas(Norwegian University of Science and Technology), Tero Aittokallio(Oslo University Hospital), Kaisa Lehti(Oslo University Hospital), Åsmund Flobak(Norwegian University of Science and Technology), Kristine Lippestad(SINTEF)
bioRxiv (Cold Spring Harbor Laboratory)
May 12, 2026
Cited by 0Open Access
Full Text

Abstract

Abstract Effective drug combination therapies can improve cancer treatment, yet the mechanistic basis of drug synergy remains poorly understood. Most computational approaches prioritize predictive accuracy over molecular mechanistic interpretability, providing hence limited insights into how synergistic effects emerge across signalling contexts. We developed Trafikk, a molecular-signalling network-based framework that simulates drug perturbations in cell line-specific computational models to mirror functional outcomes in experimental combination screens. Across two independent large-scale datasets, Trafikk identified synergistic combinations with >77% recall. Functional response predictions revealed both conserved and context-dependent mechanisms. While AKT-MEK co-inhibition consistently disrupted coordinated survival and apoptotic signalling in 742 cell lines, PI3K-BCL2 synergy arose through distinct death programs shaped by cell-context-specific network constraints. Trafikk combines predictive performance with mechanistic interpretability, capturing how and why drug synergy emerges across cellular contexts. Source code, installation instructions and usage tutorial are freely available at https://github.com/druglogics/trafikk . Abstract Figure


Related Papers

No related papers found

Powered by citation graph analysis